Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correlation of serum protein biomarkers with disease activity in psoriatic arthritis

Autor: DoQuyen Huynh, John Temple, P S Eastman, A. Kavanaugh, David L. Boyle, Joshua Hillman, E H Sasso, R Bolce, F Qureshi, T A Boyd

Publikováno v: Expert Review of Clinical Immunology. 16:335-341

Objective: To assess the correlation of serum protein biomarkers with disease activity across different domains of psoriatic arthritis (PsA).Material and methods: A cross-sectional cohort of 45 adult patients with PsA fulfilling the classification fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9887aca666b2528936a752808d4bd857
https://doi.org/10.1080/1744666x.2020.1729129

Zobrazit plný text záznamu

Taux de rétablissement de la réponse avec l’ixékizumab après l’arrêt du traitement chez des patients atteints de spondyloarthrite axiale : résultats à la semaine 104 d’une étude de retrait randomisé, contrôlée versus placebo

Autor: R.B. Landewé, D. Poddubnyy, P. Rahman, R. Bolce, S.L. Leage, J. Lisse, A. Leung, S.Y. Park, L.S. Gensler, C. Lukas

Publikováno v: Revue du Rhumatisme. 89:A149

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d12100935b0eecaad8e7a25fe65e225
https://doi.org/10.1016/j.rhum.2022.10.219

Zobrazit plný text záznamu

OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY

Autor: R. B. M. Landewé, D. Poddubnyy, P. Rahman, R. Bolce, S. Liu Leage, J. Lisse, A. Leung, S. Y. Park, L. S. Gensler

Publikováno v: Annals of the Rheumatic Diseases. 81:10-11

BackgroundCOAST-Y is the first study to evaluate the effect of continuing vs withdrawing an IL-17A antagonist, Ixekizumab (IXE) on the maintenance of disease control in patients (pts) with ankylosing spondylitis and non-radiographic axial spondyloart

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f71c9735d889286d949c167e19d6f55f
https://doi.org/10.1136/annrheumdis-2022-eular.4280

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis

Autor: C. T. Ritchlin, L. E. Kristensen, B. Strober, A. Kavanaugh, R. Bolce, J. Lisse, J. Pustizzi, N. Somani, C. Sapin, J. F. Merola

Publikováno v: Annals of the Rheumatic Diseases. 81:1590.3-1591

BackgroundThe relationship between the evolution of nail disease and the articular features of Psoriatic Arthritis (PsA) is poorly understood. There is a lack of data on the relationship between nail and joint disease, important clinical parameters o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45fd973d5a780a34011864ae9af0f65f
https://doi.org/10.1136/annrheumdis-2022-eular.711

Zobrazit plný text záznamu

POS0984 PREVALENCE OF axSpA IN PATIENTS TREATED FOR CHRONIC BACK PAIN IN CHIROPRACTIC CLINICS: THE OREGON CHIROPRACTIC AXIAL SPONDYLOARTHRITIS STUDY (ORCAS) – AN INTERIM ANALYSIS

Autor: S. Kiwalkar, S. Bhalerao, K. Phung Nguyen, R. Quinn, D. Perham, W. Malatestinic, R. Bolce, T. Hunter, P. Khurana, A. Deodhar

Publikováno v: Annals of the Rheumatic Diseases. 81:800-800

BackgroundNon-rheumatology settings such as chiropractor clinics, where chronic back pain (CBP; including chronic back, buttock, or hip pain) patients are first seen, lack consistency in referral of patients to rheumatologists where the underlying ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb6fca43052aa4dd24d958f360dee212
https://doi.org/10.1136/annrheumdis-2022-eular.2905

Zobrazit plný text záznamu

POS0930 SAFETY AND EFFICACY OF IXEKIZUMAB TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 3-YEAR CLINICAL TRIAL RESULTS FROM THE COAST PROGRAMME

Autor: A. Deodhar, D. Poddubnyy, P. Rahman, R. Bolce, S. Liu Leage, A. Kronbergs, C. Johnson, A. Leung, D. Van der Heijde

Publikováno v: Annals of the Rheumatic Diseases. 81:765.1-765

BackgroundIxekizumab (IXE) has demonstrated efficacy at week (wk) 16 which was maintained through 2 years (yrs) and was associated with a consistent safety profile in patients (pts) with r- and nr-axSpA, who are bDMARD-naïve and TNFi-experienced.1-3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26f6b9ed1c375b617e3166227377e918
https://doi.org/10.1136/annrheumdis-2022-eular.140

Zobrazit plný text záznamu

OP0034 IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SpA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS

Autor: V. Navarro-Compán, J. D. Reveille, P. Rahman, J. Maldonado-Cocco, M. Magrey, R. Bolce, D. Sandoval, S. Y. Park, A. Kronbergs, M. Rudwaleit

Publikováno v: Annals of the Rheumatic Diseases. 81:24.1-25

BackgroundIxekizumab (IXE), a high-affinity monoclonal antibody selectively targeting interleukin-17A,1 has demonstrated superior efficacy to placebo (PBO) in the treatment of patients (pts) with radiographic axial spondyloarthritis (r-axSpA) (COAST-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7363c0e4f5dc3e73c842db057698410e
https://doi.org/10.1136/annrheumdis-2022-eular.164

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání